iPS Cells & Regenerative Medicine– category –
-
Capricor Therapeutics Establishes Commercial Manufacturing for Deramiocel Cell Therapy for DMD, Reports Q2 2026 Financials
Capricor Therapeutics USA Overview Capricor Therapeutics reported its Q2 2026 financial results, highlighting commercial and manufacturing readiness for its lead product candidate, Deramiocel. This allogeneic cardiac-derived cell therapy... -
UC Santa Barbara Researchers Successfully Restore Vision in Two AMD Patients with Stem Cell Retinal Patch
CIRM (California Institute for Regenerative Medicine) UK Overview A stem cell-based retinal patch developed by UC Santa Barbara researchers successfully restored vision in two UK patients suffering from age-related macular degeneration (... -
UCSD Advances Next-Gen CAR-T & Gamma Delta T-Cell Therapies for Solid Tumors in Multiple Phase 1 Clinical Trials
UCSD USA Overview UCSD is actively pursuing multiple Phase 1 clinical trials for next-generation cell therapies targeting advanced solid tumors. Featured trials include FT825/ONO-8250, an off-the-shelf HER2 CAR-T, and A2B395, an allogene... -
Elicera Therapeutics’ CARMA Study Unveils Striking 91% Tumor Response in Relapsed/Refractory B-cell Lymphoma, Including Prior CAR T-Cell Failures
Elicera Therapeutics Sweden Overview Elicera Therapeutics has concluded patient enrollment for the Phase I segment of its CARMA study, evaluating ELC-301 in patients with relapsed or refractory B-cell lymphoma. Interim efficacy data from... -
New CAR-T Engineering Strategies Target Solid Tumor Barriers: Leveraging Real-World Data & Manufacturing Innovations
ecancer International Overview Novel engineering strategies for CAR-T cell therapy against solid tumors are focusing on enhancing T-cell anti-tumor activity and overcoming microenvironmental barriers. Recent clinical results, such as int... -
USC Viterbi Engineers Develop Ultrasound-Guided SHIFTERS Technology to Reprogram Solid Tumors for CAR-T Efficacy
USC Viterbi School of Engineering USA Overview Researchers at the USC Viterbi School of Engineering have developed a novel technology called SHIFTERS to enable CAR-T cells to effectively target solid tumors. This method uses focused ultr... -
Epicrispr Raises $90M to Advance Epigenetic Editing Drug EPI-321 for Rare Muscle Disease FSHD, Completes Phase 1 Enrollment
BioPharma Dive USA Overview Epicrispr Biotechnologies has successfully raised $90 million in Series C financing to accelerate the development of EPI-321, an epigenetic editing drug for facioscapulohumeral muscular dystrophy (FSHD). EPI-3... -
Porton Advanced Secures China NMPA Drug License to Expand CDMO Services to Commercial CGT Manufacturing
Porton Advanced China Overview Porton Advanced has been granted a Class C Drug Manufacturing License by China's NMPA, enabling it to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products. This expands their... -
NueCell Bio Launches 26,300-Square-Foot Cell Therapy Development Facility to Scale CDMO Services in San Diego
PharmaSource USA Overview NueCell Bio has launched as a dedicated cell therapy science and development services company, opening a 26,300-square-foot facility in San Diego to support translational development, process development, analyt... -
Novartis’ CAR-T Cell Therapy Tisagenlecleucel Shows Durable Efficacy in Pediatric and Young Adult ALL
CancerNetwork USA Overview Novartis' CAR-T cell therapy, tisagenlecleucel (Kymriah), continues to demonstrate durable efficacy and safety in pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia ...
